Discriminating between mild cognitive impairment and Alzheimer's disease: Validation of early Alzheimer's biomarkers by combining advanced imaging and in vitro diagnostic techniques
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/31411
Ficheiros no ítem
Metadatos do ítem
Título: | Discriminating between mild cognitive impairment and Alzheimer's disease: Validation of early Alzheimer's biomarkers by combining advanced imaging and in vitro diagnostic techniques |
Autor/a: | Aramburu Núñez, Marta |
Dirección/Titoría: | Sobrino Moreiras, Tomás Castillo Sánchez, José |
Centro/Departamento: | Universidade de Santiago de Compostela. Escola de Doutoramento Internacional (EDIUS) Universidade de Santiago de Compostela. Programa de Doutoramento en Medicina Molecular |
Palabras chave: | Alzheimer’s disease | biomarkers | diagnosis | mild cognitive impairment | tau protein | |
Data: | 2023 |
Resumo: | Alzheimer’s disease (AD) is the leading cause of dementia, implying a progressive decline of cognitive performance and limitation of social activities. In this scenario, in parallel to current research of novel treatments, it is imperative to develop new strategies for an earlier diagnosis of AD. This study has focused on the importance of different isoforms of the Tau protein involved in early pathophysiological processes of AD. Specifically, two new monoclonal antibodies (mAb) against phosphorylated tau (p-Tau) and acetylated tau (ac-Tau) have been produced, with which a clinical immunodiagnostic kit and a preclinical radiotracer for PET 89-Zirconium (89Zr)-pTau mAb have been developed for diagnostic purposes. In addition, a preclinical proof of concept of immunotherapy with p-Tau antibody has been also carried out. |
Data de Embargo: | 2024-11-16 |
URI: | http://hdl.handle.net/10347/31411 |
Dereitos: | Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Coleccións
-
- Área de Ciencias da Saúde [1262]
O ítem ten asociados os seguintes ficheiros de licenza: